Is INBX or ORKA more profitable?

Oruka Therapeutics' return on equity of -21.65% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -83.48% Oruka Therapeutics N/A -21.65% -20.88%

Does the media refer more to INBX or ORKA?

In the previous week, Oruka Therapeutics had 4 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 9 mentions for Oruka Therapeutics and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.15 beat Oruka Therapeutics' score of 0.65 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oruka Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PTCT or INBX?

In the previous week, PTC Therapeutics had 10 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 15 mentions for PTC Therapeutics and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.15 beat PTC Therapeutics' score of 0.41 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is INBX or COGT more profitable?

Cogent Biosciences' return on equity of -84.47% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -83.48% Cogent Biosciences N/A -84.47% -47.72%

Is INBX or SRRK more profitable?

Scholar Rock's return on equity of -160.19% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Inhibrx Biosciences N/A -563.90% -83.48% Scholar Rock N/A -160.19% -87.18%

Does the media favor INBX or SRRK?

In the previous week, Inhibrx Biosciences and Inhibrx Biosciences both had 5 articles in the media. Inhibrx Biosciences' average media sentiment score of 1.15 beat Scholar Rock's score of 0.40 indicating that Inhibrx Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, GRFS or INBX?

Grifols has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.60 $454.82M $0.19 39.68 Inhibrx Biosciences $1.30M 1,024.74 -$140.05M -$8.88 N/A

Does the media prefer GRFS or INBX?

In the previous week, Grifols had 1 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 6 mentions for Grifols and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.15 beat Grifols' score of 0.32 indicating that Inhibrx Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inhibrx Biosciences (INBX) Competitors

$89.11 -1.39 (-1.53%)

As of 11:33 AM Eastern

Compare

INBX vs. ORKA, PTCT, COGT, SRRK, and GRFS

Should you buy Inhibrx Biosciences stock or one of its competitors? Inhibrx Biosciences's main competitors and comparable companies include Oruka Therapeutics (ORKA), PTC Therapeutics (PTCT), Cogent Biosciences (COGT), Scholar Rock (SRRK), and Grifols (GRFS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Inhibrx Biosciences compare to Oruka Therapeutics?

Inhibrx Biosciences (NASDAQ:INBX) and Oruka Therapeutics (NASDAQ:ORKA) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 56.4% of Oruka Therapeutics shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Inhibrx Biosciences presently has a consensus target price of $197.50, indicating a potential upside of 118.23%. Oruka Therapeutics has a consensus target price of $128.91, indicating a potential upside of 74.51%. Given Inhibrx Biosciences' higher possible upside, equities research analysts plainly believe Inhibrx Biosciences is more favorable than Oruka Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Oruka Therapeutics has lower revenue, but higher earnings than Inhibrx Biosciences. Oruka Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,024.74	-$140.05M	-$8.88	N/A
Oruka Therapeutics	N/A	N/A	-$105.43M	-$2.03	N/A

In the previous week, Oruka Therapeutics had 4 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 9 mentions for Oruka Therapeutics and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.15 beat Oruka Therapeutics' score of 0.65 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oruka Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oruka Therapeutics' return on equity of -21.65% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
Oruka Therapeutics	N/A	-21.65%	-20.88%

Inhibrx Biosciences has a beta of 3.81, indicating that its share price is 281% more volatile than the broader market. Comparatively, Oruka Therapeutics has a beta of -0.37, indicating that its share price is 137% less volatile than the broader market.

Summary

Oruka Therapeutics beats Inhibrx Biosciences on 8 of the 14 factors compared between the two stocks.

How does Inhibrx Biosciences compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

PTC Therapeutics has a beta of 0.49, suggesting that its share price is 51% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.81, suggesting that its share price is 281% more volatile than the broader market.

82.5% of Inhibrx Biosciences shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, PTC Therapeutics had 10 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 15 mentions for PTC Therapeutics and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.15 beat PTC Therapeutics' score of 0.41 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibrx Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inhibrx Biosciences has a net margin of 0.00% compared to PTC Therapeutics' net margin of -3.80%. PTC Therapeutics' return on equity of 0.00% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-3.80%	N/A	-1.32%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

PTC Therapeutics presently has a consensus price target of $97.62, suggesting a potential upside of 60.05%. Inhibrx Biosciences has a consensus price target of $197.50, suggesting a potential upside of 118.23%. Given Inhibrx Biosciences' higher probable upside, analysts plainly believe Inhibrx Biosciences is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.69
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

PTC Therapeutics has higher revenue and earnings than Inhibrx Biosciences. PTC Therapeutics is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	2.94	$682.64M	-$0.58	N/A
Inhibrx Biosciences	$1.30M	1,024.74	-$140.05M	-$8.88	N/A

Summary

PTC Therapeutics beats Inhibrx Biosciences on 8 of the 15 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Cogent Biosciences?

Inhibrx Biosciences (NASDAQ:INBX) and Cogent Biosciences (NASDAQ:COGT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Cogent Biosciences' return on equity of -84.47% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
Cogent Biosciences	N/A	-84.47%	-47.72%

Inhibrx Biosciences has a beta of 3.81, suggesting that its share price is 281% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Inhibrx Biosciences has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,024.74	-$140.05M	-$8.88	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.16	N/A

Inhibrx Biosciences presently has a consensus target price of $197.50, suggesting a potential upside of 118.23%. Cogent Biosciences has a consensus target price of $51.56, suggesting a potential upside of 74.71%. Given Inhibrx Biosciences' higher possible upside, research analysts plainly believe Inhibrx Biosciences is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, Inhibrx Biosciences had 4 more articles in the media than Cogent Biosciences. MarketBeat recorded 5 mentions for Inhibrx Biosciences and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.82 beat Inhibrx Biosciences' score of 1.15 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibrx Biosciences	Positive
Cogent Biosciences	Very Positive

82.5% of Inhibrx Biosciences shares are held by institutional investors. 18.3% of Inhibrx Biosciences shares are held by insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Inhibrx Biosciences beats Cogent Biosciences on 7 of the 13 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Scholar Rock?

Inhibrx Biosciences (NASDAQ:INBX) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

82.5% of Inhibrx Biosciences shares are owned by institutional investors. Comparatively, 91.1% of Scholar Rock shares are owned by institutional investors. 18.3% of Inhibrx Biosciences shares are owned by insiders. Comparatively, 10.3% of Scholar Rock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Inhibrx Biosciences has a beta of 3.81, suggesting that its share price is 281% more volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Inhibrx Biosciences has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Inhibrx Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibrx Biosciences	$1.30M	1,024.74	-$140.05M	-$8.88	N/A
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

In the previous week, Inhibrx Biosciences and Inhibrx Biosciences both had 5 articles in the media. Inhibrx Biosciences' average media sentiment score of 1.15 beat Scholar Rock's score of 0.40 indicating that Inhibrx Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibrx Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Scholar Rock's return on equity of -160.19% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibrx Biosciences	N/A	-563.90%	-83.48%
Scholar Rock	N/A	-160.19%	-87.18%

Inhibrx Biosciences presently has a consensus target price of $197.50, indicating a potential upside of 118.23%. Scholar Rock has a consensus target price of $67.67, indicating a potential upside of 66.50%. Given Inhibrx Biosciences' higher possible upside, research analysts clearly believe Inhibrx Biosciences is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	4 Strong Buy rating(s)	2.94

Summary

Inhibrx Biosciences beats Scholar Rock on 7 of the 13 factors compared between the two stocks.

How does Inhibrx Biosciences compare to Grifols?

Grifols (NASDAQ:GRFS) and Inhibrx Biosciences (NASDAQ:INBX) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, analyst recommendations, risk and earnings.

82.5% of Inhibrx Biosciences shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Grifols had 1 more articles in the media than Inhibrx Biosciences. MarketBeat recorded 6 mentions for Grifols and 5 mentions for Inhibrx Biosciences. Inhibrx Biosciences' average media sentiment score of 1.15 beat Grifols' score of 0.32 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibrx Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.60	$454.82M	$0.19	39.68
Inhibrx Biosciences	$1.30M	1,024.74	-$140.05M	-$8.88	N/A

Grifols presently has a consensus price target of $10.00, indicating a potential upside of 32.63%. Inhibrx Biosciences has a consensus price target of $197.50, indicating a potential upside of 118.23%. Given Inhibrx Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Inhibrx Biosciences is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Inhibrx Biosciences	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Grifols has a net margin of 5.54% compared to Inhibrx Biosciences' net margin of 0.00%. Grifols' return on equity of 6.21% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Inhibrx Biosciences	N/A	-563.90%	-83.48%

Grifols has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.81, indicating that its share price is 281% more volatile than the broader market.

Summary

Inhibrx Biosciences beats Grifols on 9 of the 16 factors compared between the two stocks.

Get Inhibrx Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INBX vs. The Competition

Export

Metric	Inhibrx Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.33B	$3.93B	$7.43B	$12.86B
Dividend Yield	N/A	3.66%	2.51%	19.61%
P/E Ratio	-10.16	12.63	274.94	25.22
Price / Sales	1,019.27	1,201.64	623.57	99.68
Price / Cash	N/A	118.95	76.19	51.56
Price / Book	163.67	16.07	10.40	5.96
Net Income	-$140.05M	-$22.69M	$3.50B	$380.92M
7 Day Performance	-5.26%	-6.92%	-3.89%	-3.33%
1 Month Performance	-11.55%	-12.35%	-7.10%	-5.34%
1 Year Performance	145.95%	2.13%	1.70%	-4.58%

Inhibrx Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INBX Inhibrx Biosciences	3.5915 of 5 stars	$89.11 -1.5%	$197.50 +121.6%	+151.8%	$1.31B	$1.30M	N/A	110	Positive News Insider Trade
ORKA Oruka Therapeutics	2.6438 of 5 stars	$78.19 -2.7%	$128.91 +64.9%	+164.7%	$5.32B	N/A	N/A	68	Analyst Forecast Insider Trade
PTCT PTC Therapeutics	4.0574 of 5 stars	$59.92 -4.8%	$98.25 +64.0%	-11.0%	$5.25B	$1.73B	N/A	991	News Coverage Analyst Forecast
COGT Cogent Biosciences	2.8698 of 5 stars	$28.09 -5.7%	$51.56 +83.5%	+78.1%	$5.17B	N/A	N/A	258	Positive News
SRRK Scholar Rock	2.7357 of 5 stars	$40.52 -3.4%	$67.67 +67.0%	+25.4%	$5.11B	N/A	N/A	289	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INBX) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibrx Biosciences (INBX) Competitors

INBX vs. ORKA, PTCT, COGT, SRRK, and GRFS

How does Inhibrx Biosciences compare to Oruka Therapeutics?

Summary

How does Inhibrx Biosciences compare to PTC Therapeutics?

Summary

How does Inhibrx Biosciences compare to Cogent Biosciences?

Summary

How does Inhibrx Biosciences compare to Scholar Rock?

Summary

How does Inhibrx Biosciences compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibrx Biosciences (INBX) Competitors

INBX vs. ORKA, PTCT, COGT, SRRK, and GRFS

How does Inhibrx Biosciences compare to Oruka Therapeutics?

Do institutionals & insiders have more ownership in INBX or ORKA?

Do analysts rate INBX or ORKA?

Which has stronger earnings and valuation, INBX or ORKA?

Does the media refer more to INBX or ORKA?

Is INBX or ORKA more profitable?

Which has more risk and volatility, INBX or ORKA?

Summary

How does Inhibrx Biosciences compare to PTC Therapeutics?

Which has more volatility and risk, PTCT or INBX?

Do insiders & institutionals hold more shares of PTCT or INBX?

Does the media prefer PTCT or INBX?

Is PTCT or INBX more profitable?

Do analysts rate PTCT or INBX?

Which has preferable earnings & valuation, PTCT or INBX?

Summary

How does Inhibrx Biosciences compare to Cogent Biosciences?

Is INBX or COGT more profitable?

Which has more volatility and risk, INBX or COGT?

Which has better valuation and earnings, INBX or COGT?

Do analysts prefer INBX or COGT?

Does the media favor INBX or COGT?

Do insiders and institutionals hold more shares of INBX or COGT?

Summary

How does Inhibrx Biosciences compare to Scholar Rock?

Do institutionals & insiders have more ownership in INBX or SRRK?

Which has more volatility and risk, INBX or SRRK?

Which has higher earnings and valuation, INBX or SRRK?

Does the media favor INBX or SRRK?

Is INBX or SRRK more profitable?

Do analysts prefer INBX or SRRK?

Summary

How does Inhibrx Biosciences compare to Grifols?

Do insiders and institutionals believe in GRFS or INBX?

Does the media prefer GRFS or INBX?

Which has higher valuation and earnings, GRFS or INBX?

Do analysts prefer GRFS or INBX?

Is GRFS or INBX more profitable?

Which has more risk and volatility, GRFS or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX vs. The Competition

Inhibrx Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools